EUVIMEDEUVIMED entdecken
Kohortenstudie

Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study

Esteban Fuentes-Valenzuela, Francisco Javier García-Alonso iD, Carlos Maroto-Martín, Laura Juan Casamayor, José Antonio Garrote, Rosendo Almendros Muñoz, Ángel De Prado, Alejando Vara Castrodeza, María Ángeles Marinero, Raquel Calleja Carbajosa, Jesús Barrio iD

Inflammatory Bowel Diseases · 2023

DOI: 10.1093/ibd/izac259 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Inflammatory Bowel Diseases, 2023. Verfasst von Esteban Fuentes-Valenzuela und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Hospital Universitario Rio Hortega, Valladolid, St. Dulzaina, 2, 47012 Valladolid, Spain. Hauptthemen laut MEDLINE: Tumor Necrosis Factor Inhibitors, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Carriers of the human leucocyte antigen variant HLADQA1*05 (rs2097432) are at risk of developing antibodies against infliximab and adalimumab with reduced tumor necrosis factor (TNF) antagonist persistence. The impact of proactive therapeutic drug monitoring (PTDM) on this association has been barely assessed.

Methods

We conducted a retrospective single-center cohort study including patients with inflammatory bowel disease starting anti-TNF therapy between January 2017 and March 2021. Proactive therapeutic drug monitoring was defined as periodic drug level measurement (≥2 determinations during the first year of treatment and ≥1/annual determination during the following years), regardless of clinical condition, followed by dose optimization. Variables associated with treatment persistence were assessed with multivariable Cox regression analysis.

Results

A total of 112 patients were included, 52 (46.4%) HLA-DQA1*05 carriers, with a median follow-up of 73.9 (interquartile range, 35.4-133.1) weeks. Combination therapy with thiopurines was more frequent among HLA-DQA1*05 noncarriers (28 [46.7%] vs 12 [23.1%]; P = .01). Clinical remission rates at week 14 (77.9% vs 73.9%; P = .69) and 56 (73.2% vs 68.4%; P = .64) were similar between HLA-DQA1*05 noncarriers and carriers. Drug persistence was higher among HLA-DQA1*05 carriers (hazard ratio [HR], 0.32; 95% confidence interval, 0.14-0.71; P = .01). Multivariable Cox regression analysis identified systemic steroids at anti-TNF initiation (HR, 4; 95% confidence interval, 1.7-9.7) as a risk factor and HLA-DQA1*05 carriers (HR, 0.31; 95% confidence interval, 0.12–0.81) as a protective factor of treatment cessation.

Conclusion

In adult patients with PTDM, a positive HLA-DQA1*05 genotype does not associate a higher risk of treatment cessation nor worse clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Necrosis Factor InhibitorsInflammatory Bowel DiseasesHumansAdultRetrospective StudiesCohort StudiesDrug MonitoringInfliximabAdalimumabGenotypeTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

AntiDQA1*05HLATNFproactive drug monitoring

Substanzen

Tumor Necrosis Factor InhibitorsInfliximabAdalimumabTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Gastroenterology Department, Hospital Universitario Rio Hortega, Valladolid, St. Dulzaina, 2, 47012 Valladolid, Spain.
  • Department of Laboratory Medicine, Hospital Universitario Rio Hortega, Valladolid, St. Dulzaina, 2, 47012 Valladolid, Spain.
  • Department of Pharmacy, Hospital Universitario Rio Hortega, Valladolid, St. Dulzaina, 2, 47012 Valladolid, Spain.
  • Radiology Department. Hospital Universitario Rio Hortega, Valladolid, St. Dulzaina, 2, 47012 Valladolid, Spain.

ORCID-Profile: Francisco Javier García-Alonso, Jesús Barrio

Zitieren

APA

Fuentes-Valenzuela, E., García-Alonso, F. J., Maroto-Martín, C., Juan Casamayor, L., Garrote, J. A., Almendros Muñoz, R., De Prado, Á., Vara Castrodeza, A., Marinero, M. Á., Calleja Carbajosa, R., & Barrio, J. (2023). Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izac259

Vancouver

Fuentes-Valenzuela E, García-Alonso FJ, Maroto-Martín C, Juan Casamayor L, Garrote JA, Almendros Muñoz R, et al. Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study. Inflammatory Bowel Diseases. 2023. doi:10.1093/ibd/izac259

BibTeX
@article{FuentesValenzuela2023,
  author = {Fuentes-Valenzuela, Esteban and García-Alonso, Francisco Javier and Maroto-Martín, Carlos and Juan Casamayor, Laura and Garrote, José Antonio and Almendros Muñoz, Rosendo and De Prado, Ángel and Vara Castrodeza, Alejando and Marinero, María Ángeles and Calleja Carbajosa, Raquel and Barrio, Jesús},
  title = {Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2023},
  doi = {10.1093/ibd/izac259}
}
Kostenlos starten →